Aspirin/omeprazole 325/40

Drug Profile

Aspirin/omeprazole 325/40

Alternative Names: Aspirin enteric-coated (EC)/omeprazole immediate-release (IR) 325/40; Omeprazole/aspirin 40mg/325mg; PA 032540; PA 325; PA 32540; Yosprala 325/40

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 11 Jan 2017 Aralez Pharmaceuticals has patent protection for aspirin/omeprazole 325/40 in USA
  • 03 Oct 2016 Launched for Cardiovascular disorders (Prevention of relapse) in USA (PO)
  • 15 Sep 2016 Updated adverse events data from two phase III trials in Cardiovascular disorders (Prevention of relapse) released by Aralez Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top